within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA24_Abatacept;

model Abatacept
  extends Pharmacolibrary.Drugs.ATC.L.L04AA24;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L04AA24</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Abatacept is a selective T-cell co-stimulation modulator used for the treatment of moderate to severe rheumatoid arthritis and other autoimmune diseases. It is a fusion protein composed of the extracellular domain of human cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) linked to the modified Fc portion of human IgG1. Abatacept is approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult rheumatoid arthritis patients following intravenous administration at a dose of ~10 mg/kg; parameter values represent commonly reported population means.</p><h4>References</h4><ol><li><p>Li, X, et al., &amp; Murthy, B (2019). Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis. <i>Journal of clinical pharmacology</i> 59(2) 245–257. DOI:<a href=\"https://doi.org/10.1002/jcph.1308\">10.1002/jcph.1308</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30229926/\">https://pubmed.ncbi.nlm.nih.gov/30229926</a></p></li><li><p>Balevic, SJ, et al., &amp; Hornik, CP (2024). Abatacept Pharmacokinetics and Exposure Response in Patients Hospitalized With COVID-19: A Secondary Analysis of the ACTIV-1 IM Randomized Clinical Trial. <i>JAMA network open</i> 7(4) e247615–None. DOI:<a href=\"https://doi.org/10.1001/jamanetworkopen.2024.7615\">10.1001/jamanetworkopen.2024.7615</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38662372/\">https://pubmed.ncbi.nlm.nih.gov/38662372</a></p></li><li><p>Hervey, PS, &amp; Keam, SJ (2006). Abatacept. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 20(1) 53–62. DOI:<a href=\"https://doi.org/10.2165/00063030-200620010-00004\">10.2165/00063030-200620010-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16573350/\">https://pubmed.ncbi.nlm.nih.gov/16573350</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Abatacept;
